HK inno.N Corporation (195940.KQ)

KRW 36600.0

(-1.75%)

Market Cap (In KRW)

1036.87 Billion

Revenue (In KRW)

828.9 Billion

Net Income (In KRW)

47.19 Billion

Avg. Volume

363.42 Thousand

Currency
KRW
Country
Open
-
Prev. Close
-
Day Range
-
Year Range
34300.0-52000.0
PE
-
EPS
-
Beta Value
0.602
ISIN
KR7195940002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Industry
CEO
Mr. Dal-Won Kwak
Employee Count
-
Website
https://www.inno-n.com
Ipo Date
2021-08-09
Details
HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.